Table 2.
Enzyme inhibitors by second, third and fourth generation for 2013 only (1.3%)
| Enzyme inhibitors | Number of claims 2013 | Second | Third | Fourth | Other (patch, etc.) |
|---|---|---|---|---|---|
| Valproic acid | 1294 | 429 (33.2%) | 381 (29.4%) | 473 (36.6%) | 11 (0.8%) |
| Diazepam + other benzodiazepines | 6044 | 1481 (24.5%) | 1607 (26.6%) | 2278 (37.7%) | 678 (11.2%) |
| Atrovastatin | 1144 | 249 (21.8%) | 365 (31.9) | 496 (43.4%) | 34 (3.0%) |
| Rosuvastatin | 990 | 158 (16.0%) | 293 (29.6%) | 508 (51.3%) | 31 (3.1%) |
| Verapamil | 54 | 16 (29.6%) | 27 (50%) | 5 (9.3%) | 6 (11.1%) |
| Diltiazam | 38 | 11 (28.9%) | 12 (31.6%) | 15 (39.5%) | – |
| Etorcoxib | 633 | 200 (31.6%) | 172 (27.2%) | 215 (34.0%) | 46 (7.3%) |
| Cimetidine | 23 | 0 | 9 (39.1%) | 14 (60.9%) | – |
| Fluconazole | 1556 | 506 (32.5%) | 287 (18.4%) | 622 (40.0%) | 141 (9.1%) |